Artificial intelligence (AI) is increasingly reshaping diagnostic pathology, with breast pathology representing one of the most advanced and clinically impactful areas of adoption. Despite rapid progress, many practicing pathologists remain unfamiliar with core AI concepts and their practical implications. This review provides a concise and accessible overview of AI in breast pathology, focusing on foundational principles, current clinical applications, and future directions.

UT Health San Antonio cancer researcher Amelie G. Ramirez, DrPH, aims to enhance recovery for breast cancer survivors through the study of therapeutic yoga with a two-year, $400,000 grant from Susan G. Komen.

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

A study published in Current Molecular Pharmacology reveals that the natural alkaloid gramine selectively inhibits triple‑negative breast cancer by triggering ferroptosis through a novel CUL3‑MTDH axis. Gramine binds CUL3, reducing MTDH ubiquitination and degradation, which downregulates ferroptosis suppressors SLC3A2 and GPX4. In vivo, gramine significantly suppressed tumor growth with minimal toxicity, positioning it as a promising therapeutic candidate for this aggressive cancer.